The Filing Desk

Cumberland Pharmaceuticals vs Xilio Therapeutics

Cumberland Pharmaceuticals CPIX · Xilio Therapeutics XLO · Pharmaceuticals

Cumberland Pharmaceuticals reported revenue of $44 million in fiscal 2025, about the same as Xilio Therapeutics' $44 million in fiscal 2025. Cumberland Pharmaceuticals' revenue grew 17.6% in its latest year, and Xilio Therapeutics' grew 589.9%. Cumberland Pharmaceuticals had an operating margin of -6.3%, against -95.9% at Xilio Therapeutics. Free cash flow was $5 million at Cumberland Pharmaceuticals and −$6 million at Xilio Therapeutics.

Side by side

Cumberland PharmaceuticalsXilio Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$44M$44M
Revenue growth17.6%589.9%
Revenue growth a year, last 5 years3.5%—
Gross margin85.0%—
Operating margin−6.3%−95.9%
Net margin−6.4%−80.0%
Free cash flow$5M−$6M
Free cash flow margin10.9%−12.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count5.7%118.7%
Last close$6.30$7.51
P/E at the last close1.4×—
Insider trades, last 12 months—bought $43,950, sold $5,668
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Cumberland PharmaceuticalsXilio Therapeutics
Operating margin
Percent of revenue
Cumberland PharmaceuticalsXilio Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Cumberland PharmaceuticalsXilio Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cumberland Pharmaceuticals and Xilio Therapeutics pages.